Abstract:Eight genetically distinct families of the enzyme carbonic anhydrase (CA, EC 4.2.1.1) were described in organisms allover the phylogenetic tree. They catalyze the hydration of CO2 to bicarbonate and protons, and are involved in pH regulation, chemosensing and metabolism. The 15 α-CA isoforms present in humans are pharmacological drug targets known for decades, their inhibitors being used as diuretics, antiglaucoma, antiepileptic or antiobesity drugs, as well as for the management of acute mountain sickness, idiopathic intracranial hypertension and recently, as antitumor theragnostic agents. Other potential applications include the use of CA inhibitors (CAIs) in inflammatory conditions, cerebral ischemia, neuropathic pain, or for Alzheimer's/Parkinson's disease management. CAs from pathogenic bacteria, fungi, protozoans and nematodes started to be considered as drug targets in recent years, with notable advances registered ultimately. CAIs have a complex multipharmacology probably unique to this enzyme, which has been exploited intensely but may lead to other relevant applications in the future, due to the emergence of drug design approaches which afforded highly isoform-selective compounds for most α-CAs known to date. They belong to a multitude of chemical classes (sulfonamides and isosteres, (iso)coumarins and related compounds, mono- and dithiocarbamates, selenols, ninhydrines, boronic acids, benzoxaboroles, etc). The polypharmacology of CAIs will also be discussed since drugs originally discovered for the treatment of non-CA related conditions (topiramate, zonisamide, celecoxib, pazopanib, thiazide and high-ceiling diuretics) show efective inhibition against many CAs, which led to their repurposing for diverse pharmacological applications. Significance Statement Carbonic anhydrase inhibitors have multiple pharmacologic applications as diuretics, antiglaucoma, antiepileptic, antiobesity, anti-acute mountain sickness, anti-idiopathic intracranial hypertension and as antitumor drugs. Their use in inflammatory conditions, cerebral ischemia, neuropathic pain, or neurodegenerations started to be investigated recently. Parasite carbonic anhydrases are also drug targets for antiinfectives with novel mechanisms of action which can by pass drug resistance to commonly used such agents. Drugs discovered for the management of other conditions that effectively inhibit these enzymes exert interesting polypharmacologic effects.

Novel carbonic anhydrase inhibitors for the treatment of Helicobacter pylori infection

Helicobacter pylori CAs inhibition

Carbonic Anhydrases: New Perspectives on Protein Functional Role and Inhibition in Helicobacter pylori

An overview of novel antimicrobial carbonic anhydrase inhibitors

Cyclization of acyl thiosemicarbazides led to new Helicobacter pylori α‐carbonic anhydrase inhibitors

Azobenzenesulfonamide Carbonic Anhydrase Inhibitors as New Weapons to Fight Helicobacter pylori: Synthesis, Bioactivity Evaluation, In Vivo Toxicity, and Computational Studies

Bacterial, fungal and protozoan carbonic anhydrases as drug targets

Multi- and poly-pharmacology of carbonic anhydrase inhibitors

Selective Inhibition of Helicobacter pylori Carbonic Anhydrases by Carvacrol and Thymol Could Impair Biofilm Production and the Release of Outer Membrane Vesicles

Challenges for developing bacterial CA inhibitors as novel antibiotics

Carbonic anhydrase inhibition/activation: trip of a scientist around the world in the search of novel chemotypes and drug targets

Drug interactions of carbonic anhydrase inhibitors and activators

Carbonic anhydrase and bacterial metabolism: a chance for antibacterial drug discovery

Molecular design of hydroxamic acid-based derivatives as urease inhibitors of Helicobacter pylori

Development of Penicillin-Based Carbonic Anhydrase Inhibitors Targeting Multidrug-Resistant Neisseria gonorrhoeae

Synthesis, characterization, DFT studies, and in silico biological evaluation of novel dipeptide-sulphonamide derivatives against Helicobacter pylori receptors

An Overview of the Bacterial Carbonic Anhydrases

Arylamino Containing Hydroxamic Acids As Potent Urease Inhibitors for the Treatment of Helicobacter Pylori Infection.

Cinnamaldehyde: An effective component of Cinnamomum cassia inhibiting Helicobacter pylori

Design and synthesis of novel anti-urease imidazothiazole derivatives with promising antibacterial activity against Helicobacter pylori

New indications for FDA-approved drugs: selective inhibition of growth of Helicobacter pylori by covalent allosteric regulation of urease